-
MLN2238: Proteasome Assay Design and Optimization
2026-09-30
This scenario-based guide explains how MLN2238 (SKU A4008) can help researchers design more controlled proteasome-inhibition, viability, proliferation, and cytotoxicity experiments. It connects biochemical potency, formulation, storage, assay optimization, and ROS/JNK/CREB biology to practical laboratory decisions.
-
Acifran Workflows for HCAR2/HCAR3 Research
2026-09-30
Acifran supports matched HCAR2/GPR109A and HCAR3/GPR109B experiments that connect receptor activation with cAMP and lipid-pathway readouts. This guide translates cryo-EM findings into practical dose planning, structure-guided validation, and troubleshooting strategies for metabolic disorder research.
-
DiscoveryProbe Protease Inhibitor Library Workflow
2026-09-29
Build a defensible protease inhibition workflow by pairing biochemical screening with cell-based confirmation, apoptosis assay readouts, and orthogonal counterscreens. The DiscoveryProbe™ Protease Inhibitor Library combines broad chemical coverage with automation-ready formatting for cancer research, infectious disease research, and mechanistic target validation.
-
Verbascoside for PKC/NF-κB Signaling Studies
2026-09-29
Verbascoside provides a practical chemical perturbation tool for linking PKC/NF-κB activity with osteoclastogenesis research and exploratory neuroinflammation assays. Its approximately 4.8 μM cellular IC50 in RANKL-treated macrophage models supports dose-ranging, while careful solvent control is essential for reproducible results.
-
Bacitracin (B1670): Protocol and QC Guide
2026-09-28
Bacitracin (B1670) provides a controlled peptide antibiotic reagent for antibacterial research involving bacterial cell wall and peptidoglycan synthesis. This guide covers solvent selection, storage, assay controls, and interpretation limits; the material is for scientific research only and is not intended for diagnostic, clinical, or medical use.
-
Pentoxifylline Dampens LPS Responses in Preterm Monocytes
2026-09-28
Schüller and colleagues tested pentoxifylline (PTX) against LPS-induced monocyte activation in preterm and term infants and adults, combining flow-cytometric, cytokine, phagocytosis, and TLR4 measurements. PTX reduced several inflammatory responses across age groups, while selected effects differed in neonatal samples—findings that support age-aware experimental design but do not establish clinical efficacy or a JAK-inhibitor mechanism.
-
DNase I (RNase-free) for Cleaner Cancer Assays
2026-09-27
DNase I (RNase-free) helps researchers control DNA carryover in RNA-focused workflows. This article connects careful sample preparation to interpreting new evidence on CAF-derived lactate, ANTXR1 lactylation, and oxaliplatin resistance—while clarifying what nuclease treatment can and cannot establish.
-
Protease Inhibition in HCC: From Screen to Mechanism
2026-09-26
Learn how protease inhibition screens can reveal—and misassign—regulators of the PSMD14–CARM1–FERMT1 pathway in hepatocellular carcinoma. This mechanistic guide connects the DiscoveryProbe Protease Inhibitor Library to practical assay choices, orthogonal validation, and careful interpretation of cell-based results.
-
MACC1–HNRNPH1 Control of IRAK1 Splicing in LUAD
2026-09-25
The study links MACC1 to alternative splicing of IRAK1 in lung adenocarcinoma, showing that MACC1 works with HNRNPH1 to favor the long IRAK1 isoform over the shorter form. Its findings position RNA-splicing control as a mechanism through which MACC1 can promote tumor progression and suggest a pathway for further investigation, rather than an established clinical target.
-
Fludarabine Workflows for DNA Synthesis Inhibition
2026-09-25
Use Fludarabine to build DNA-replication, cell-cycle, and apoptosis studies in leukemia and multiple myeloma models, then test immune-facing endpoints with careful controls. This workflow connects its direct cytotoxic effects to recent evidence that combination lymphodepleting chemotherapy can reshape neoantigen presentation—without assuming Fludarabine alone explains that effect.
-
From Nest Ecology to PCR: Translational Lessons
2026-09-24
A study of disease spread in ambrosia beetle nests shows why spatial context matters—and how careful PCR workflow design can help translational researchers connect biological observations to reproducible molecular evidence.
-
High-Content Screening of Schistosome Stem Cells
2026-09-24
The study establishes an imaging-based assay to quantify neoblast proliferation in developmentally advanced Schistosoma mansoni schistosomula, then applies it to a 280-compound stem cell-focused screen. Its prioritized compounds disrupted parasite development and stem cell proliferation, illustrating how cellular phenotypes can complement conventional motility and morphology readouts in anti-schistosomal discovery.
-
Ruxolitinib Drives Dual Death in Anaplastic Thyroid Cancer
2026-09-23
A 2024 study links JAK1/2–STAT3 inhibition by ruxolitinib to reduced DRP1 transcription, impaired mitochondrial fission, and caspase-dependent apoptosis plus GSDME-mediated pyroptosis in anaplastic thyroid cancer. The findings provide a mechanistic rationale for studying this pathway in ATC, while leaving clinical efficacy, optimal dosing, and generalizability to other diseases unresolved.
-
High-Fidelity PCR for Translational Immunotherapy
2026-09-23
Translational oncology depends on more than biological insight: it also depends on sequence-accurate constructs, reproducible amplification, and defensible molecular quality control. This article connects the bufalin–CRISPR/Cas9 nanomedicine strategy reported in Materials Today Bio with the mechanistic advantages and workflow decisions surrounding 2X HyperFusion™ High-Fidelity Master Mix.
-
TROLL-8 mRNA: Dendritic Cell Workflow
2026-09-22
Build a practical screening workflow around TROLL-8 mRNA for dendritic-cell uptake, expression, and adaptive-immunity studies. The approach combines formulation quality control with receptor-aware assays inspired by a PEG-free, rhamnolipid-stabilized mRNA nanovaccine platform.